An up­date on the End­points busi­ness mod­el — and how your com­pa­ny can di­rect­ly sup­port it

Pic­tured: The print-op­ti­mized ver­sion of End­points’ 2018 New Drug Ap­provals re­port. All paid sub­scribers will re­ceive a di­rect link to down­load the PDF + a copy of all our Q1 pay­wall sto­ries in print­able form, too.

Sign-up for En­ter­prise (com­pa­ny plan)
Sign-up for In­sid­er (in­di­vid­ual plan)


I want to give read­ers an up­date on the busi­ness front at End­points News, which is strong.

Two and a half years in — we’re prof­itable, about 14 peo­ple on the team and grow­ing, and 75,000 unique bio­phar­ma read­ers con­sume our news across all plat­forms on a week­ly ba­sis. Of that, 31,000 are what we con­sid­er “ba­sic sub­scribers” who re­ceive our dai­ly email re­ports and have opened or clicked on them in the last month, but haven’t up­grad­ed to paid sta­tus. And at the top we have 8,300 pre­mi­um sub­scribers who ei­ther di­rect­ly sup­port the work or are em­ployed at a com­pa­ny that does.

We reg­u­lar­ly scrub our email read­er­ship, too.

We’ve built a glob­al events fran­chise and con­vened over 2,000 at­ten­dees over the last 12 months in San Fran­cis­co, Boston, Lon­don, and Shang­hai. Lat­er this month we’ll be an­nounc­ing venues and dates for our en­tire 2019 line­up.

John Car­roll speaks at the US-Chi­na Bio­phar­ma In­no­va­tion and In­vest­ment Sum­mit in Shang­hai on Oc­to­ber 23, 2018

Click on the im­age to see the full-sized ver­sion


And we’ve done all of this with­out rais­ing any VC cash.

End­points is built to with­stand the storms en­velop­ing dig­i­tal me­dia to­day thanks to the di­rect sup­port of our En­ter­prise and In­sid­er sub­scribers.  We’re hir­ing new jour­nal­ists, plan to dou­ble the au­di­ence, and have moved in­to a new head­quar­ters in Lawrence, Kansas that’ll serve as the nerve-cen­ter for End­points’ next stage of in­no­va­tion. New hires in mar­ket­ing, sales, and op­er­a­tions are in the works now to sup­port that. There’s a web­site re­vamp on tap. And there’s just so much more news we’d like to cov­er in trans­la­tion­al sci­ence and out­sourc­ing.

Most im­por­tant­ly: Our fi­nan­cial in­cen­tives are tied to pro­duc­ing a jour­nal­ism prod­uct that serves the core bio­phar­ma read­er.

Haven’t joined yet? Now is a great time and you can see one of the ben­e­fits above: a print (yes, print!) ver­sion of the 2018 class of new drug ap­provals. You’ll al­so get ac­cess to the lat­est edi­tion of bio­phar­ma’s top 100 VCs, and the en­tire pay­wall li­brary.

The most im­por­tant way you can di­rect­ly sup­port End­points is hav­ing your com­pa­ny sub­scribe to our $1,000/year flat-rate En­ter­prise plan (signup link). That’s an “un­lim­it­ed li­cense” for every em­ploy­ee un­der your cor­po­rate ban­ner. All of your col­leagues get ac­cess to pay­wall con­tent, reprint rights, PDF ex­port, and your HR team gets two pre­mi­um job post­ings at End­points Ca­reers. We have a VIP sup­port team who’ll work with you to get End­points set up for the rest of your team, too.

It’s a great val­ue, and you’re sup­port­ing the most im­por­tant part of our mod­el. The pric­ing is trans­par­ent and so is our re­new­al process.

For in­di­vid­u­als, we of­fer the In­sid­er plan at $200/year. Ex­tra ben­e­fits on top of the pay­wall ac­cess in­clude dis­count­ed rates to our ma­jor glob­al events line­up.

We’re al­so start­ing a se­ries of sub­scriber-on­ly net­work­ing mix­ers for In­sid­ers. The very first one will be in Durham, NC on Thurs­day Feb­ru­ary 21 at 6pm. I’ll be there along with our VP/Part­ner­ships Mike Peck. In­sid­ers will get an email next week with signup de­tails on this one and our fu­ture slate.

Grow­ing Plans

We’re go­ing through a ma­jor plat­form over­haul this year.

The look and feel of End­points hasn’t changed since we launched in June 2016. The orig­i­nal goal of our de­sign is to de­liv­er news with­out un­nec­es­sary or­na­ments, with a user ex­pe­ri­ence that feels fa­mil­iar no mat­ter what de­vice you’re on. But we’ve pub­lished over 5,000 news ar­ti­cles and near­ly 700 dai­ly re­ports now in the End­points style, and with that ex­pe­ri­ence we’ve iden­ti­fied a num­ber of ar­eas we can im­prove on. Some of it will be in­cre­men­tal like bet­ter search and im­prov­ing the archives. Oth­ers will be more vis­i­ble and feel like brand new fea­tures.

Ad­ver­tis­ing

Sub­scrip­tions are the lifeblood of this com­pa­ny. But in or­der to de­vel­op a sus­tained im­pact be­fit­ting a ma­jor news or­ga­ni­za­tion, ar­ti­cles must be able to trav­el far and wide, eas­i­ly dis­cov­er­able by new au­di­ences. Oth­er­wise, we run the risk of be­com­ing an in­sid­ers-on­ly re­port.

That is where ad­ver­tis­ing comes in. But noth­ing we do there is tra­di­tion­al.

I don’t be­lieve in squeez­ing web pages hard for lit­tle juice. That’s es­sen­tial­ly what many news pub­lish­ers do when you see pro­mot­ed links and ads that are at best ir­rel­e­vant and at worst have fol­lowed you around the In­ter­net to sell you some­thing you searched on ear­li­er. That kind of ap­proach cheap­ens the qual­i­ty of the con­tent sur­round­ing it, in my view. It has no place on a busi­ness news web­site.

Every ad unit you see on End­points is pur­chased in-house. These are high qual­i­ty im­pres­sions that are rel­e­vant to bio­phar­ma, brought to you by ad­ver­tis­ers that have been vet­ted. Our busi­ness team is led by Mike Peck, who comes to End­points af­ter serv­ing as a VP at Forbes and the New York Times. Mar­ket­ing pros can reach him at mike@end­pointsnews.com.

Busi­ness Mod­el

Sub­scrip­tions, events, ad­ver­tis­ing — in or­der of im­por­tance, that is the End­points busi­ness mod­el. Our mis­sion is to pro­duce the best dai­ly news re­port in bio­phar­ma, writ­ten for our core read­ers, but to make it as wide­ly avail­able as pos­si­ble so it has an im­pact and is dis­cov­er­able by new read­ers.

If you need End­points, we def­i­nite­ly need you. Again the best way to sup­port us is hav­ing your com­pa­ny sub­scribe to our $1,000/year flat-rate En­ter­prise plan (signup link). In­di­vid­u­als can signup for In­sid­er here.

To all of you who’ve joined — thank you. We’re build­ing some­thing to­geth­er.

Hal Barron. GSK

GSK's Hal Bar­ron her­alds their sec­ond pos­i­tive PhI­II for cru­cial an­ti-BC­MA ther­a­py, point­ing to a push for quick OKs in a crowd­ed field

Hal Barron has his second positive round of Phase III data in hand for his anti-BCMA antibody drug conjugate belantamab mafodotin (GSK2857916). And GSK’s research chief says the data paves the way for their drive in search of an FDA approval for treating multiple myeloma. 

It’s hard to overestimate the importance of this drug for GSK, a cornerstone of Barron’s campaign to make a dramatic impact on the oncology market and provide some long-lost excitement for the pharma giant’s pipeline. They’re putting this BCMA program at the front of that charge — looking to lead a host of rivals all aimed at the same target.

Martin Shkreli [via Getty]

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is reporting that the lead drug he co-invented flopped in a pivotal trial. Fosmetpantotenate flunked both the primary and key secondary endpoints in a placebo-controlled trial for a rare disease called pantothenate kinase-associated neurodegeneration, or PKAN.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

AstraZeneca is in a hurry.

We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.

That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology
ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development
CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at help@endpointsnews.com with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

Bob Smith, Pfizer

Pfiz­er is mak­ing a $500M state­ment to­day: Here’s how you be­come a lead play­er in the boom­ing gene ther­a­py sec­tor

Three years ago, Pfizer anted up $150 million in cash to buy Bamboo Therapeutics in Chapel Hill, NC as it cautiously stuck a toe in the small gene therapy pool of research and development.

Company execs followed up a year later with a $100 million expansion of the manufacturing operations they picked up in that deal for the UNC spinout, which came with $495 million in milestones.

And now they’re really going for it.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

Video: Putting the AI in R&D — with Badhri Srini­vasan, Tony Wood, Rosana Kapeller, Hugo Ceule­mans, Saurabh Sa­ha and Shoibal Dat­ta

During BIO this year, I had a chance to moderate a panel among some of the top tech experts in biopharma on their real-world use of artificial intelligence in R&D. There’s been a lot said about the potential of AI, but I wanted to explore more about what some of the larger players are actually doing with this technology today, and how they see it advancing in the future. It was a fascinating exchange, which you can see here. The transcript has been edited for brevity and clarity. — John Carroll

UP­DAT­ED: As­traZeneca’s Imfinzi/treme com­bo strikes out — again — in lung can­cer. Is it time for last rites?

AstraZeneca bet big on the future of their PD-L1 Imfinzi combined with the experimental CTLA-4 drug tremelimumab. But once again it’s gone down to defeat in a major Phase III study — while adding damage to the theory involving targeting cancer with a high tumor mutational burden.

Early Wednesday the pharma giant announced that their NEPTUNE study had failed, with the combination unable to beat standard chemo at overall survival in high TMB cases of advanced non-small cell lung cancer. We won’t get hard data until later in the year, but the drumbeat of failures will call into question what — if any — future this combination can have left.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

Am­gen, Al­ler­gan biosim­i­lar of Roche's block­buster Rit­ux­an clears an­oth­er US piv­otal study 

Novartis $NVS may have given up, but Amgen $AMGN and Allergan $AGN are plowing ahead with their knockoff of Roche’s blockbuster biologic Rituxan in the United States.

Their copycat, ABP 798, was found to have a clinically equivalent impact as Rituxan — meeting the main goal of the study involving CD20-positive B-cell non-Hodgkin’s lymphoma patients. This is the second trial supporting the profile of the biosimilar. In January, it came through with positive PK results in patients with rheumatoid arthritis.